Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 434,058 shares of the company's stock after selling 25,474 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.51% of Syndax Pharmaceuticals worth $5,738,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SNDX. Barclays PLC boosted its stake in shares of Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company's stock valued at $3,612,000 after purchasing an additional 110,535 shares during the period. KBC Group NV boosted its stake in shares of Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after purchasing an additional 3,559 shares during the period. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at $26,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock valued at $239,000 after purchasing an additional 1,732 shares during the period. Finally, abrdn plc purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at $1,313,000.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock traded down $0.23 during trading hours on Wednesday, reaching $10.96. The stock had a trading volume of 1,945,108 shares, compared to its average volume of 1,793,941. The company has a market cap of $943.08 million, a price-to-earnings ratio of -3.02 and a beta of 0.82. The business's 50 day moving average price is $11.35 and its 200-day moving average price is $13.33. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. The business's revenue for the quarter was up 1900.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.85) earnings per share. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analysts Set New Price Targets

SNDX has been the subject of a number of research reports. Citigroup lowered their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Guggenheim reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank upped their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).